Press & Media

About Fanconi Anemia and FCF

Fanconi anemia (known as FA) is a genetic DNA repair disease that can affect every system of the body. In people with FA, cells have less ability to repair themselves and as a result, errors in these cells will increase over time, causing cancer and often bone marrow failure. The Fanconi Cancer Foundation (FCF) is the leading organization worldwide dedicated to curing this disease. Our mission is to improve the lives of people affected by Fanconi anemia and associated cancers worldwide by funding exceptional research and empowering our community.

Media Contacts

For media inquiries, please reach out to:
Sherri Van Ravenhorst, Communications Director
Email: sherri@fanconi.org

Media Resources

Access our collection of media resources to support your coverage of the Fanconi Cancer Foundation:

Are you an FA community member looking to share your story with the media? We can help!

Testimonials and Impact Stories

Read inspiring quotes and stories from families and leaders that highlight the impact of our work.

The Latest

News & Events

2025 Research Updates

Research is the answer to one day making FA a treatable, manageable disease. Here, you'll discover the most recent strides in FA research and activities funded by FCF. Every quarter, we'll bring you updates on newly funded grants, ongoing projects, and significant milestones.

Read More >

Behind the Research with Meng Wang

In this edition of our Behind the Research series, we’re excited to introduce Dr. Meng Wang, a physician-scientist at Cornell University whose work is shedding light on a little-known but powerful driver of DNA damage in Fanconi anemia: formaldehyde. Dr....

Read More >

What Families Told Us: A Deeper Look at Life with Fanconi Anemia (FA)

Everything we do at the Fanconi Cancer Foundation (FCF) starts with the individual, because understanding the lived experience of FA is essential to improving care, advancing research, and strengthening support. As gene therapy and other promising treatments move from clinical...

Read More >